(Q37535829)

20 August 2017

2 references

23 October 2022

Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer (English)

1 reference

20 August 2017

0 references

0 references

0 references

1 reference

1 reference

Newcastle disease virus

object named as

Newcastle disease virus

1 reference

Volker Schirrmacher

1

1 reference

PubMed ID

19565923

20 August 2017

Philippe Fournier

series ordinal

2

1 reference

PubMed ID

19565923

20 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

Methods in Molecular Biology

20 August 2017

2 references

20 August 2017

23 October 2022

542

1 reference

20 August 2017

565-605

1 reference

Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma

20 August 2017

1 reference

12 December 2020

Tumor response and 4 year survival-data of patients with advanced renal-cell carcinoma treated with autologous tumor vaccine and subcutaneous R-IL-2 and IFN-alpha(2b).

1 reference

12 December 2020

Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus

1 reference

12 December 2020

Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis.

1 reference

12 December 2020

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

1 reference

12 December 2020

The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors

1 reference

12 December 2020

Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application.

1 reference

12 December 2020

Selective expression of an interleukin-12 receptor component by human T helper 1 cells

1 reference

12 December 2020

Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus

1 reference

12 December 2020

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme

1 reference

12 December 2020

Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens

1 reference

12 December 2020

Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication

1 reference

12 December 2020

T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides.

1 reference

12 December 2020

A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV.

1 reference

12 December 2020

Pathogen recognition with Toll-like receptors

1 reference

12 December 2020

Molecular cross-talk between the TRAIL and interferon signaling pathways.

1 reference

12 December 2020

Overlapping and distinct mechanisms regulating IRF-3 and IRF-7 function

1 reference

12 December 2020

Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage

1 reference

12 December 2020

Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells

1 reference

12 December 2020

On the origins and relationships of Newcastle disease virus vaccine strains Hertfordshire and Mukteswar, and virulent strain Herts'33.

1 reference

12 December 2020

Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner

1 reference

12 December 2020

NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.

1 reference

12 December 2020

Requirements for the assembly and release of Newcastle disease virus-like particles

1 reference

12 December 2020

T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity

1 reference

12 December 2020

Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H).

1 reference

12 December 2020

Viruses know it all: new insights into IFN networks

1 reference

12 December 2020

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization

1 reference

12 December 2020

Viruses as immunological adjuvants in cancer

1 reference

12 December 2020

Integrity of membrane lipid rafts is necessary for the ordered assembly and release of infectious Newcastle disease virus particles

1 reference

12 December 2020

T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.

1 reference

12 December 2020

Oncolytic viral therapies - the clinical experience

1 reference

12 December 2020

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma

1 reference

12 December 2020

T cell-independent interleukin 15Ralpha signals are required for bystander proliferation

1 reference

12 December 2020

Cell type-specific involvement of RIG-I in antiviral response

1 reference

12 December 2020

[Position of the Scientific Medical Council on the antitumor studies conducted in Hungary on the Newcastle disease virus]

1 reference

12 December 2020

Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy

1 reference

12 December 2020

Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death

1 reference

12 December 2020

Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer

1 reference

12 December 2020

Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta

1 reference

12 December 2020

1 reference

12 December 2020

Tolerance, danger, and the extended family

1 reference

12 December 2020

Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response

1 reference

12 December 2020

Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus

1 reference

12 December 2020

Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza

1 reference

12 December 2020

Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction

1 reference

12 December 2020

Newcastle disease virus: macromolecules and opportunities

1 reference

12 December 2020

Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients.

1 reference

12 December 2020

Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial

1 reference

12 December 2020

Negative-strand RNA viruses: applications to biotechnology

1 reference

12 December 2020

Immunization with virus-modified tumor cells.

1 reference

12 December 2020

Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus

1 reference

12 December 2020

Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation

1 reference

12 December 2020

Recovery of negative-strand RNA viruses from plasmid DNAs: a positive approach revitalizes a negative field

1 reference

12 December 2020

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.

1 reference

12 December 2020

Newcastle disease virus antibodies in human sera.

1 reference

12 December 2020

Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma

1 reference

12 December 2020

Generation of recombinant lentogenic Newcastle disease virus from cDNA.

1 reference

12 December 2020

Interferon Production in Mouse Spleen Cells and Mouse Fibroblasts (L Cells) Stimulated by Various Strains of Newcastle Disease Virus

1 reference

12 December 2020

Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response

1 reference

12 December 2020

Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus

1 reference

12 December 2020

Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta

1 reference

12 December 2020

Do T lymphocytes correlate danger signals to antigen?

1 reference

12 December 2020

Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein.

1 reference

12 December 2020

Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence

1 reference

12 December 2020

In vitro and clinical characterisation of a newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients

1 reference

12 December 2020

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

1 reference

12 December 2020

1 reference

12 December 2020

The danger model: a renewed sense of self

1 reference

12 December 2020

Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus

1 reference

12 December 2020

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

1 reference

12 December 2020

Newcastle disease virus selectively kills human tumor cells

1 reference

12 December 2020

A recombinant newcastle disease virus with low-level V protein expression is immunogenic and lacks pathogenicity for chicken embryos

1 reference

12 December 2020

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity

1 reference

12 December 2020

In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein.

1 reference

12 December 2020

Links between innate and adaptive immunity via type I interferon

1 reference

12 December 2020

An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins

1 reference

12 December 2020

Newcastle disease virus may enter cells by caveolae-mediated endocytosis

1 reference

12 December 2020

Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation

1 reference

12 December 2020

Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy

1 reference

12 December 2020

Paramyxovirus membrane fusion: lessons from the F and HN atomic structures

1 reference

12 December 2020

Molecular biology of Newcastle disease virus

1 reference

12 December 2020

Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview

1 reference

12 December 2020

Danger signals: SOS to the immune system

1 reference

12 December 2020

Treatment of human cancer with mumps virus

1 reference

12 December 2020

Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns

1 reference

12 December 2020

Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus.

1 reference

12 December 2020

An optimized clinical regimen for the oncolytic virus PV701.

1 reference

12 December 2020

Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence

1 reference

12 December 2020

Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine

1 reference

12 December 2020

Viruses in the treatment of cancer

1 reference

12 December 2020

Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA.

1 reference

12 December 2020

Recombinant Newcastle disease virus as a vaccine vector

1 reference

12 December 2020

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

1 reference

12 December 2020

Maturation, activation, and protection of dendritic cells induced by double-stranded RNA

1 reference

12 December 2020

Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV).

1 reference

12 December 2020

Gangliosides as paramyxovirus receptor. Structural requirement of sialo-oligosaccharides in receptors for hemagglutinating virus of Japan (Sendai virus) and Newcastle disease virus

1 reference

12 December 2020

Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells

1 reference

12 December 2020

Oncolytic virus therapy--foreword

1 reference

12 December 2020

p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines

1 reference

12 December 2020

Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures

1 reference

12 December 2020

Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus.

1 reference

12 December 2020

Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback

1 reference

12 December 2020

Structure and function of the protein kinase R.

1 reference

12 December 2020

Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy

1 reference

12 December 2020

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

1 reference

12 December 2020

A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.

1 reference

12 December 2020

Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates

1 reference

12 December 2020

Newcastle disease virus (NDV): brief history of its oncolytic strains

1 reference

12 December 2020

Toll-like receptor 3 promotes cross-priming to virus-infected cells.

1 reference

12 December 2020

Gangliosides and N-glycoproteins function as Newcastle disease virus receptors

1 reference

12 December 2020

Reactions of human sera to avian adenoviruses and Newcastle disease virus

1 reference

12 December 2020

Newcastle disease virus activates macrophages for anti-tumor activity

1 reference

12 December 2020

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

1 reference

12 December 2020

Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity

1 reference

12 December 2020

Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B.

1 reference

12 December 2020

Viral hemagglutinin augments peptide-specific cytotoxic T cell responses

1 reference

12 December 2020

RIG-I: tri-ing to discriminate between self and non-self RNA.

1 reference

12 December 2020

Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus

1 reference

12 December 2020

RNA viruses as virotherapy agents

1 reference

12 December 2020

Genome replication of Newcastle disease virus: involvement of the rule-of-six

1 reference

12 December 2020

High-level expression of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease virus

1 reference

12 December 2020

The makings of a tumor rejection antigen

1 reference

12 December 2020

Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae

1 reference

12 December 2020

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects

1 reference

12 December 2020

A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate

1 reference

12 December 2020

Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein

1 reference

12 December 2020

The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA.

1 reference

12 December 2020

Attenuated veterinary virus vaccine for the treatment of cancer.

1 reference

12 December 2020

OBSERVATIONS ON THE REPEATED ADMINISTRATION OF VIRUSES TO A PATIENT WITH ACUTE LEUKEMIA. A PRELIMINARY REPORT.

1 reference

12 December 2020

Augmentation of tumor cell immunogenicity by viruses--an approach to specific immunotherapy of cancer

1 reference

12 December 2020

Professional type I interferon-producing cells--a unique subpopulation of dendritic cells

1 reference

12 December 2020

T cell-mediated immunotherapy of metastases: state of the art in 2005.

1 reference

12 December 2020

5'-Triphosphate RNA is the ligand for RIG-I

1 reference

12 December 2020

New developments in the virus therapy of cancer: a historical review

1 reference

12 December 2020

Scientific interest in Newcastle disease virus is reviving

1 reference

12 December 2020

Viral oncolysates as human tumor vaccines

1 reference

12 December 2020

Paramyxovirus reverse genetics is coming of age.

1 reference

12 December 2020

Small self-RNA generated by RNase L amplifies antiviral innate immunity

1 reference

12 December 2020

Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses.

1 reference

12 December 2020

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additiona

1 reference

12 December 2020

Recombinant Newcastle Disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits

1 reference

12 December 2020

IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.

1 reference

12 December 2020

Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes

1 reference

12 December 2020

Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

1 reference

12 December 2020

Genes coding for tumor antigens recognized by cytolytic T lymphocytes

1 reference

12 December 2020

Interferon, Mx, and viral countermeasures

1 reference

12 December 2020

Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. II. Influence of the local inflammatory response on immune reactivity.

1 reference

12 December 2020

10.1007/978-1-59745-561-9_30

Identifiers

DOI

1 reference

20 August 2017

0 references

1 reference

PubMed ID

19565923